Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More

Mar 02nd, 2022

Octave is transforming multiple sclerosis (MS) care with comprehensive measurement and management tools. At ACTRIMS Forum 2022, the Octave team was proud to share how we’re helping physicians manage treatment for MS patients. “We are focused on an entire, comprehensive solution to manage patients with #MS,” said Ferhan Qureshi, Vice President of Biomarker Product Development at #Octave. “We have an enhanced MRI imaging program. We have a patient care insights program. And then we have blood-based biomarkers.” Read more about our MS Precision Care solution from 360Dx https://bit.ly/3vQkdid

Get in Touch

Please reach out and we’ll be in touch soon.